thalidomide has been researched along with Lichen Planus in 19 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Lichen Planus: An inflammatory, pruritic disease of the skin and mucous membranes, which can be either generalized or localized. It is characterized by distinctive purplish, flat-topped papules having a predilection for the trunk and flexor surfaces. The lesions may be discrete or coalesce to form plaques. Histologically, there is a saw-tooth pattern of epidermal hyperplasia and vacuolar alteration of the basal layer of the epidermis along with an intense upper dermal inflammatory infiltrate composed predominantly of T-cells. Etiology is unknown.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The US FDA-approved thalidomide for the treatment of chronic recurrent/severe erythema nodosum leprosum." | 5.12 | Thalidomide: an experience in therapeutic outcome and adverse reactions. ( Gupta, M; Mahajan, VK; Ranjan, N; Shanker, V; Sharma, NL; Sharma, VC, 2007) |
| "Thalidomide was first introduced in the 1950s as a sedative but was quickly removed from the market after it was linked to cases of severe birth defects." | 2.43 | Thalidomide: dermatological indications, mechanisms of action and side-effects. ( Hsu, S; Huang, DB; Pang, KR; Tyring, SK; Wu, JJ, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 10 (52.63) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X | 1 |
| Wang, S | 1 |
| Skullerud, KH | 1 |
| Gjersvik, P | 1 |
| Pripp, AH | 1 |
| Qvigstad, E | 1 |
| Helgesen, ALO | 1 |
| Arora, P | 1 |
| Sardana, K | 1 |
| Gautam, RK | 1 |
| Malhotra, P | 1 |
| Zhang, L | 1 |
| Au, S | 1 |
| Aronson, IK | 1 |
| Moura, AK | 1 |
| Moure, ER | 1 |
| Romiti, R | 1 |
| Abdel-Karim, A | 1 |
| Frezzini, C | 1 |
| Viggor, S | 1 |
| Davidson, LE | 1 |
| Thornhill, MH | 1 |
| Yeoman, CM | 1 |
| Rose, AE | 1 |
| Patel, U | 1 |
| Chu, J | 1 |
| Patel, R | 1 |
| Meehan, S | 1 |
| Latkowski, JA | 1 |
| Paul, J | 1 |
| Foss, CE | 1 |
| Hirano, SA | 1 |
| Cunningham, TD | 1 |
| Pariser, DM | 1 |
| Boyd, AS | 1 |
| King, LE | 1 |
| Eisman, S | 1 |
| Orteu, CH | 1 |
| Jouanique, C | 1 |
| Reygagne, P | 1 |
| Bachelez, H | 1 |
| Dubertret, L | 1 |
| Wu, JJ | 1 |
| Huang, DB | 1 |
| Pang, KR | 1 |
| Hsu, S | 2 |
| Tyring, SK | 1 |
| Petropoulou, H | 1 |
| Kontochristopoulos, G | 1 |
| Kalogirou, O | 1 |
| Panteri, I | 1 |
| Zakopoulou, N | 1 |
| Sharma, NL | 1 |
| Sharma, VC | 1 |
| Mahajan, VK | 1 |
| Shanker, V | 1 |
| Ranjan, N | 1 |
| Gupta, M | 1 |
| Dereure, O | 1 |
| Basset-Seguin, N | 1 |
| Guilhou, JJ | 1 |
| Saano, V | 1 |
| Moraes, M | 1 |
| Russo, G | 1 |
| George, SJ | 1 |
| Naafs, B | 1 |
| Faber, WR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label Pilot Study to Evaluate the Safety and Efficacy of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus[NCT01041625] | Phase 2 | 10 participants (Anticipated) | Interventional | 2010-02-28 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for thalidomide and Lichen Planus
| Article | Year |
|---|---|
Erythrodermic lichen planus.
Topics: Aged; Chills; Dermatitis, Exfoliative; Glucocorticoids; Humans; Immunologic Factors; Itraconazole; L | 2011 |
Thalidomide: dermatological indications, mechanisms of action and side-effects.
Topics: Adult; Behcet Syndrome; Dermatologic Agents; Erythema; Graft vs Host Disease; Histiocytosis, Langerh | 2005 |
[New therapeutic application of thalidomide].
Topics: Autoimmune Diseases; Colitis, Ulcerative; Erythema Multiforme; Female; Histiocytosis; Humans; Immuno | 1996 |
Thalidomide and its dermatologic uses.
Topics: Acquired Immunodeficiency Syndrome; Behcet Syndrome; Dermatologic Agents; Erythema Nodosum; Facial D | 2001 |
5 trials available for thalidomide and Lichen Planus
| Article | Year |
|---|---|
Apremilast for genital erosive lichen planus in women (the AP-GELP Study): study protocol for a randomised placebo-controlled clinical trial.
Topics: Adult; Female; Genitalia; Humans; Lichen Planus; Norway; Quality of Life; Randomized Controlled Tria | 2021 |
Treatment of cutaneous lichen planus with thalidomide.
Topics: Aged; Female; Humans; Immunosuppressive Agents; Lichen Planus; Male; Middle Aged; Thalidomide | 2009 |
An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: a case series.
Topics: Humans; Lichen Planus; Pilot Projects; Thalidomide | 2013 |
Thalidomide is ineffective in the treatment of lichen planopilaris.
Topics: Adult; Alopecia; Female; Humans; Lichen Planus; Photography; Thalidomide; Treatment Failure | 2004 |
Thalidomide: an experience in therapeutic outcome and adverse reactions.
Topics: Adult; Anti-Inflammatory Agents; Behcet Syndrome; Erythema Nodosum; Female; Humans; Leprosy; Lichen | 2007 |
10 other studies available for thalidomide and Lichen Planus
| Article | Year |
|---|---|
Case of erythrodermic lichen planus successful treated with thalidomide monotherapy.
Topics: Administration, Oral; Dermatitis, Exfoliative; Humans; Lichen Planus; Male; Middle Aged; Skin; Thali | 2020 |
Low dose thalidomide monotherapy for the treatment of recalcitrant erosive lichen planus.
Topics: Dose-Response Relationship, Drug; Female; Foot Dermatoses; Hand Dermatoses; Humans; Immunosuppressiv | 2019 |
Successful long-term thalidomide therapy for discoid lupus erythematosus-lichen planus overlap syndrome.
Topics: Adult; Drug Administration Schedule; Female; Humans; Immunosuppressive Agents; Lichen Planus; Lupus | 2014 |
Dyskeratosis congenita: a case report.
Topics: Anemia; Child; Diagnosis, Differential; Dyskeratosis Congenita; Humans; Immunologic Factors; Lichen | 2009 |
Thalidomide-induced remission of lichen planopilaris.
Topics: Administration, Oral; Adult; Dermatologic Agents; Drug Administration Schedule; Female; Follow-Up St | 2002 |
Recalcitrant erosive flexural lichen planus: successful treatment with a combination of thalidomide and 0.1% tacrolimus ointment.
Topics: Aged; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Lichen Planus; Tacrolimus | 2004 |
Effective treatment of erosive lichen planus with thalidomide and topical tacrolimus.
Topics: Administration, Topical; Humans; Immunosuppressive Agents; Lichen Planus; Lichen Planus, Oral; Male; | 2006 |
Erosive lichen planus: dramatic response to thalidomide.
Topics: Female; Humans; Immunosuppressive Agents; Lichen Planus; Middle Aged; Thalidomide | 1996 |
Lichen planopilaris treated with thalidomide.
Topics: Adult; Alopecia; Female; Humans; Lichen Planus; Scalp Dermatoses; Thalidomide | 2001 |
Thalidomide therapy. An open trial.
Topics: Adult; Aged; Central Nervous System Diseases; Erythema Multiforme; Female; Humans; Lichen Planus; Lu | 1985 |